Current Edition


UK watchdog slaps AZ, Allergan, GSK, Sanofi and Brittania for marketing breaches

When UK-based AstraZeneca announced trial data in November 2020 showing its vaccine was highly effective in preventing COVID-19, a senior AZ global executive based in …

Continue Reading →

GlaxoSmithKline to leave landmark global HQ after split-up as consumer health business plots £120M new home

GlaxoSmithKline isn’t just making changes with its U.S. operations. The company is now exploring a new location for its global headquarters amid a historic business …

Continue Reading →

CEOs of AbbVie, BMS, Lilly, GSK and more raise concerns about Washington’s intensifying drug-pricing push

As officials in Washington weigh contentious drug-pricing measures, there’s even more evidence that pharma companies are worried about potential reform. In an open letter to …

Continue Reading →

‘New GSK’ shows strength amid investor pressure, but Shingrix still needs to regain its footing

As activist investor Elliott Management turns up the heat on GlaxoSmithKline, CEO Emma Walmsley’s new vision for the company is showing strength. But while Glaxo’s …

Continue Reading →

Owlstone Medical’s Breath Biopsy Platform integrated into GSK’s Phase II Respiratory Disease Clinical Trial

Owlstone Medical Ltd, a diagnostics company developing a breathalyzer for disease, today announced that GSK, a world leader in respiratory, will incorporate Owlstone Medical’s Breath …

Continue Reading →

GSK study shows COPD ‘superiority’ for Anoro Ellipta versus Stiolto Respimat

GlaxoSmithKline’s (GSK) study showed that Anoro Ellipta is more effective than Stiolto Respimat in improving lung function in patients with chronic obstructive pulmonary disease (COPD). …

Continue Reading →